Zypadhera (olanxapine) is an atypical antipsychotic formulated as a powder, which is mixed with a dissolution fluid and given as depot injection. (Olz LAI (Long-acting injection)).
Olz LAI has the same effect on schizophrenia as olanzapine tablets.
Olz LAI is more expensive than tablets in corresponding dose. Olz LAI costs almost the same as Risperdal Depot and can be used on the same indications, but it is significant more expensive than the typical antipsychotics.
The side effects of Olz LAI are the same as treatment with olanzapine tablets except of the possibility of developing side effects by accidental intravascular injection.
Zypadhera was marketed the 13th of July 2009. Zypadhera is on prescription and under the rules of general reimbursement.
IRF states, that treatment with depot injections with typical antipsychotics in most cases is a favourable treatment of schizophrenic patients. Zypadhera should be reserved to patients with severe schizophrenia with compliance problems, and olanzapines side effect profile should be considered before the treatment with Olz LAI is initiated.